Should I Have Teprotumumab or Surgery?

Update Item Information
Identifier 20230315_nanos_surgery1_06
Title Should I Have Teprotumumab or Surgery?
Creator Alison V. Crum
Affiliation John A. Moran Eye Center, University of Utah, Salt Lake City, UT
Subject Thyroid Orbitopathy; Thyroid Eye Disease; Teprotumumab; Proptosis; Diplopia
Description Pathophysiology of thyroid eye disease/thyroid orbitopathy and teprotumumab: In orbitopathy, it is believed that there is a cross reaction of thyroid auto-antibodies with the thyrotropin receptor (TSHR) and the insulin growth factor receptor (IGFR) on orbital fibroblasts.
Date 2023-03
Language eng
Format application/pdf
Type Text
Source 2023 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of NANOS Annual Meeting 2023: Ophthalmic Surgery in the Neuro-Ophthalmic Patient
Collection Neuro-Ophthalmology Virtual Education Library: NANOS Annual Meeting Collection: https://novel.utah.edu/collection/nanos-annual-meeting-collection/
Publisher North American Neuro-Ophthalmology Society
Holding Institution Spencer S. Eccles Health Sciences Library, University of Utah
Rights Management Copyright 2023. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
ARK ark:/87278/s6sxhzqn
Context URL The NANOS Annual Meeting Neuro-Ophthalmology Collection: https://novel.utah.edu/collection/NAM/toc/
Setname ehsl_novel_nam
ID 2309975
Reference URL https://collections.lib.utah.edu/ark:/87278/s6sxhzqn